Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 12, 2026
SEALSQ (LAES) Holds Near $2.60 After -4% Decline Over 30 Days

SEALSQ (LAES) Holds Near $2.60 After -4% Decline Over 30 Days

Key Takeaways

  • As of the August 12, 2026 intraday session, LAES traded near $2.60, down about 4% from the July 13, 2026 close of $2.71 over the trailing 30 days.
  • The modest move keeps the stock in consolidation below its 50-day and 200-day moving averages, within a 52-week range of $1.99 to $8.71.
  • Preliminary H1 2026 revenue of roughly $11 million represented approximately 120% year-over-year growth, with fiscal 2026 revenue guidance for 50% to 100% growth reaffirmed.
  • Post-quantum catalysts accumulated during the period, including a GlobalFoundries memorandum of understanding, a $5 million Quobly agreement, and the launch of Miraex photonics commercialization.
  • Liquidity remains a core strength, with about $495 million in cash and short-term investments as of June 30, 2026, against modest debt.

LAES Price Action and Market Context

SEALSQ shares have moved into a holding pattern after a volatile stretch. LAES traded around $2.60 during the August 12, 2026 session, compared with a closing price of $2.71 on July 13, 2026 — a decline of roughly 4% across the trailing 30 days. The stock remains below its 50-day moving average near $2.88 and its 200-day moving average near $3.67, while the 14-day Relative Strength Index has hovered near neutral territory. The shares have traded between $1.99 and $8.71 over the past 52 weeks, reflecting the news-driven, high-volatility character of the post-quantum and semiconductor security theme. Market capitalization sits near $570 million, with trading volume moderating in early August relative to the elevated activity seen earlier in the summer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

SEALSQ’s Business and Competitive Position

SEALSQ Corp designs, develops, and markets secure semiconductors and post-quantum cryptography solutions. Its portfolio includes VaultIC secure elements, quantum-resistant RISC-V secure chips, secure ARM platform products, smart-card reader chips, and public key infrastructure and provisioning services, including the INeS certificate management platform and custom ASIC design through IC'Alps. The company serves industries such as smart energy and metering, smart home and consumer IoT, automotive and EV charging, aerospace and defense, medical, logistics, and luxury goods. SEALSQ was founded in 2022, is headquartered in Cointrin, Switzerland, and operates as a subsidiary of WISeKey International Holding. Investors follow the stock primarily for its positioning in hardware-based post-quantum security, a theme supported by rising regulatory pressure to replace encryption vulnerable to quantum computing. From what I see, the company’s focus on quantum-resistant hardware gives it a distinct edge in a rapidly evolving space.

Recent Developments Supporting LAES

The trailing 30 days were defined by steady operational announcements rather than a single market-moving event. In early July, SEALSQ reported preliminary H1 2026 revenue of approximately $11 million, up about 120% year over year, with preliminary Q2 revenue near $7 million compared with $4 million in Q1. Management also reaffirmed full-year 2026 guidance for revenue growth of 50% to 100%.

On the partnership front, SEALSQ and GlobalFoundries announced a memorandum of understanding to co-develop secure semiconductor platforms, post-quantum cryptography, and related quantum computing technologies. SEALSQ also signed a $5 million commercial agreement with Quobly to integrate post-quantum security into silicon quantum computing platforms and announced a partnership with L5 Cartronics to develop secure IoT connectivity modules.

Product and certification updates reinforced the technology narrative. The company reported that its QS7001 post-quantum secure element obtained NIST SP 800-90B Entropy Source Validation and completed Common Criteria fault-injection and side-channel resistance testing. SEALSQ launched the commercial phase of Miraex quantum photonics technology following its acquisition and appointed Daniel Brau as Chief Quantum Officer. Despite the steady news flow, the share price has consolidated rather than re-rated, suggesting investors are weighing near-term execution and valuation against a longer-dated quantum-security opportunity. One thing that stands out is how these partnerships are accumulating without immediate price reaction.

2026 Outlook and Key Milestones to Watch

The most important near-term milestones center on certification and commercialization. SEALSQ expects initial production revenue from its QS7001 secure element and QVault Trusted Platform Module products toward the latter part of 2026, pending Common Criteria EAL5+ and related certification timelines. The company has cited an active business pipeline exceeding $225 million in potential opportunities through 2029, including more than $60 million linked to post-quantum products, though conversion remains subject to customer validation and technical integration.

Investors should also monitor the pace of revenue conversion from recent partnerships, progress on the SEALQuantum vertical stack, and the September deployment phase of the SEALQuantum.com initiative. Regulatory drivers such as CNSA 2.0 timelines, French ANSSI post-quantum mandates, and broader cyber-resilience requirements could support demand, but adoption cycles in the semiconductor industry are typically long. Risks include continued net losses, a premium valuation on trailing sales, potential share dilution after significant capital raises, elevated short interest, and dependence on early-stage quantum-security adoption. The next earnings update is scheduled for September 9, 2026, based on current estimates. I’m watching this closely as execution on the pipeline will be critical.

Using AI Tools for Deeper Stock Analysis

In my own process, I frequently review automated trading approaches alongside fundamental work. Tickeron’s AI Trading Bots provide a range of strategies that can help surface ideas in volatile sectors like post-quantum semiconductors. The platform’s Trending AI Robots section highlights currently relevant bots, which serves as a useful starting point for additional due diligence on names such as LAES.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LAES

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


LAES in +4.47% Uptrend, growing for three consecutive days on August 07, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LAES advanced for three days, in of 128 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LAES's RSI Indicator exited the oversold zone, of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on LAES as a result. In of 55 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for LAES just turned positive on August 03, 2026. Looking at past instances where LAES's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .

LAES may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAES declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for LAES entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.294) is normal, around the industry mean (8.255). P/E Ratio (0.000) is within average values for comparable stocks, (166.349). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.917). LAES has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (19.841) is also within normal values, averaging (48.472).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. LAES’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAES’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Broadcom Inc. (NASDAQ:AVGO), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), Analog Devices (NASDAQ:ADI), QUALCOMM (NASDAQ:QCOM).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 189.91B. The market cap for tickers in the group ranges from 13.43K to 5.43T. NVDA holds the highest valuation in this group at 5.43T. The lowest valued company is CYBL at 13.43K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 5%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 46%. DIOD experienced the highest price growth at 17%, while LASR experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -56%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 53
Price Growth Rating: 49
SMR Rating: 76
Profit Risk Rating: 73
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
LAES
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry Semiconductors

Profile
Details
Industry
N/A
Address
Avenue Louis-Casai 58
Phone
+41 225943000
Employees
185
Web
https://www.sealsq.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.